Mylan has formed a partnership with Atomo Diagnostics to expand access to HIV self-testing products in developing and under-developed countries.
Mylan has gained exclusive rights to commercialise Atomo Diagnostics’ in-vitro HIV rapid diagnostic test products in more than 100 countries in Africa, Asia, the Middle East, and Latin America through the agreement.
Go deeper with GlobalData
Based in the US, Mylan is a pharmaceutical company engaged in the development of over-the-counter (OTC) drugs, while Atomo Diagnostics is a medical device company engaged in the development of in-vitro diagnostic products.
The partnership will enable the two companies to provide all-in-one test devices, designed to improve functionality and ease-of-use when compared to current multi-component diagnostic tests.
Daiichi Sankyo has signed a clinical research collaboration agreement with Merck’s subsidiary to evaluate its investigational HER2 targeting antibody drug conjugate DS-8201 and Keytruda® (pembrolizumab) in HER2 expressing advanced/metastatic breast and HER2 mutant non-small cell lung cancers.
DS-8201 is designed to target and deliver chemotherapy inside cancer cells, while Keytruda® is the first anti-PD-1 (programmed death receptor-1) therapy indicated for the treatment of unresectable or metastatic melanoma.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDaiichi Sankyo will conduct a two-part, multi-centre, open-label study to evaluate the safety and efficacy of DS-8201 and Keytruda® in cancer patients across the US and Europe.
Based in Japan, Daiichi Sankyo is a pharmaceutical company engaged in the development of therapies in the areas of hypertension and diabetes, while Merck is a healthcare solutions provider based in the US.
Takeda Pharmaceutical has signed a commercialisation agreement with Molecular Templates to develop protein-based oncology therapies for cancer treatment.
The two companies will focus on the development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients suffering from multiple myeloma.
Molecular Templates will receive an upfront payment of $30m from Takeda and up to $632.5m in milestone payments upon exercising its co-development option, as per the the agreement.
Based in Japan, Takeda is engaged in the development of pharmaceuticals for metabolic and cardiovascular diseases, while Molecular Templates is a US-based clinical-stage biopharmaceutical company engaged in the development of therapeutics for cancer.
